Wyeth announced late Friday that it won FDA approval for Pristiq, its next-generation version of the antidepressant Effexor. Wyeth was looking for an approval of Pristiq to offset the considerable losses [1] that are likely to follow Effexor's loss of patent protection in 2010. Report [2]
Links:
[1] http://www.fiercepharma.com/story/sun-copycat-cut-500m-wyeth-sales/2007-12-20
[2] http://www.fiercebiotech.com/story/fda-oks-wyeth-s-antidepressant-pristiq/2008-03-03